[Form 4] Lifevantage Corporation Insider Trading Activity
Kristen Cunningham, Chief Sales Officer of LifeVantage Corp (LFVN), reported changes in her beneficial ownership on a Form 4 covering transactions dated 08/31/2025. The filing shows conversion/acquisition of 17,752 and 26,150 performance restricted stock units (PRSUs) into common stock at no cash price, an ESPP purchase of 254 shares, and a sale of 21,801 common shares at $13.10 per share. After the transactions, reported beneficial ownership totals shown range between 134,357 and 160,507 shares depending on which line is referenced; derivative holdings converted on a one-for-one basis into common stock.
Kristen Cunningham, Chief Sales Officer di LifeVantage Corp (LFVN), ha segnalato variazioni nella sua titolarità effettiva tramite un Modulo 4 relativo a operazioni datate 31/08/2025. La comunicazione indica la conversione/acquisizione di 17.752 e 26.150 performance restricted stock unit (PRSUs) in azioni ordinarie a titolo gratuito, un acquisto ESPP di 254 azioni e la vendita di 21.801 azioni ordinarie al prezzo di $13,10 per azione. Dopo le operazioni, la partecipazione beneficiaria riportata risulta compresa tra 134.357 e 160.507 azioni a seconda della riga di riferimento; i titoli derivati sono stati convertiti in azioni ordinarie con rapporto uno a uno.
Kristen Cunningham, Chief Sales Officer de LifeVantage Corp (LFVN), informó cambios en su propiedad beneficiaria mediante un Formulario 4 relativo a transacciones con fecha 31/08/2025. El documento refleja la conversión/adquisición de 17.752 y 26.150 unidades restringidas por desempeño (PRSUs) en acciones ordinarias sin coste, una compra ESPP de 254 acciones y la venta de 21.801 acciones ordinarias a $13,10 por acción. Tras las operaciones, la participación beneficiaria notificada oscila entre 134.357 y 160.507 acciones según la línea consultada; las posiciones derivadas se convirtieron en acciones ordinarias en una proporción uno a uno.
Kristen Cunningham, LifeVantage Corp (LFVN)의 Chief Sales Officer는 2025-08-31자 거래를 포함한 소유 관련 변동을 Form 4로 보고했습니다. 제출서에는 17,752 및 26,150 성과 제한주식단위(PRSUs)가 무상으로 보통주로 전환/취득된 것, ESPP를 통한 254주 매수, 그리고 보통주 21,801주를 주당 $13.10에 매도한 사실이 기재되어 있습니다. 거래 후 보고된 실질 소유는 참조한 항목에 따라 134,357주에서 160,507주 사이이며, 파생 보유는 1대1 비율로 보통주로 전환되었습니다.
Kristen Cunningham, Chief Sales Officer de LifeVantage Corp (LFVN), a déclaré des changements dans sa détention bénéficiaire via un Formulaire 4 couvrant des opérations datées du 31/08/2025. Le dépôt indique la conversion/acquisition de 17 752 et 26 150 unités d'actions restreintes liées à la performance (PRSUs) en actions ordinaires sans contrepartie financière, un achat ESPP de 254 actions et la vente de 21 801 actions ordinaires au prix de $13,10 par action. Après ces opérations, la détention bénéficiaire déclarée varie entre 134 357 et 160 507 actions selon la ligne consultée; les instruments dérivés ont été convertis en actions ordinaires à raison d'une pour une.
Kristen Cunningham, Chief Sales Officer von LifeVantage Corp (LFVN), meldete Änderungen ihres wirtschaftlichen Eigentums in einem Form 4 für Transaktionen datiert 31.08.2025. Die Einreichung zeigt die Umwandlung/Erwerb von 17.752 und 26.150 performance-restricted Stock Units (PRSUs) in Stammaktien ohne Barzahlung, einen ESPP-Kauf von 254 Aktien sowie den Verkauf von 21.801 Stammaktien zu $13,10 je Aktie. Nach den Transaktionen liegt das gemeldete wirtschaftliche Eigentum je nach gewählter Zeile zwischen 134.357 und 160.507 Aktien; derivative Bestände wurden eins zu eins in Stammaktien umgewandelt.
- Converted PRSUs to common stock totaling 17,752 and 26,150 units, increasing equity alignment with shareholders
- Participated in ESPP with a purchase of 254 shares, indicating continued employee ownership
- Disclosures reference grant dates and one-for-one conversion, improving transparency
- Sold 21,801 shares at $13.10, representing insider liquidity that partially reduces holdings
- Beneficial ownership figures vary by line (134,357 to 160,507), which may require careful reconciliation by investors
Insights
TL;DR: Insider activity shows mixed transactions: PRSU conversions and an ESPP buy alongside a notable open-market sale.
The filing documents non-cash PRSU conversions totaling 43,902 units (17,752 + 26,150) that convert one-for-one into common shares, increasing share exposure without cash outlay. The ESPP purchase of 254 shares is routine employee participation. The sale of 21,801 shares at $13.10 partially offsets those increases and represents realized insider liquidity. Overall, the activity is typical compensation-related vesting plus a voluntary sale and does not by itself indicate a material change to company fundamentals.
TL;DR: Transactions appear consistent with executive compensation vesting and routine insider selling; disclosures are timely and complete.
The report identifies PRSU grants from prior years (grants dated Aug 24, 2023 and Aug 26, 2024) that vested or converted on 08/31/2025 and are disclosed as required. The presence of an ESPP purchase and a contemporaneous open-market sale suggests portfolio rebalancing or personal liquidity rather than governance concerns. The Form 4 is signed via power of attorney and includes explanatory footnotes about grant dates and one-for-one conversion, aligning with standard disclosure practice.
Kristen Cunningham, Chief Sales Officer di LifeVantage Corp (LFVN), ha segnalato variazioni nella sua titolarità effettiva tramite un Modulo 4 relativo a operazioni datate 31/08/2025. La comunicazione indica la conversione/acquisizione di 17.752 e 26.150 performance restricted stock unit (PRSUs) in azioni ordinarie a titolo gratuito, un acquisto ESPP di 254 azioni e la vendita di 21.801 azioni ordinarie al prezzo di $13,10 per azione. Dopo le operazioni, la partecipazione beneficiaria riportata risulta compresa tra 134.357 e 160.507 azioni a seconda della riga di riferimento; i titoli derivati sono stati convertiti in azioni ordinarie con rapporto uno a uno.
Kristen Cunningham, Chief Sales Officer de LifeVantage Corp (LFVN), informó cambios en su propiedad beneficiaria mediante un Formulario 4 relativo a transacciones con fecha 31/08/2025. El documento refleja la conversión/adquisición de 17.752 y 26.150 unidades restringidas por desempeño (PRSUs) en acciones ordinarias sin coste, una compra ESPP de 254 acciones y la venta de 21.801 acciones ordinarias a $13,10 por acción. Tras las operaciones, la participación beneficiaria notificada oscila entre 134.357 y 160.507 acciones según la línea consultada; las posiciones derivadas se convirtieron en acciones ordinarias en una proporción uno a uno.
Kristen Cunningham, LifeVantage Corp (LFVN)의 Chief Sales Officer는 2025-08-31자 거래를 포함한 소유 관련 변동을 Form 4로 보고했습니다. 제출서에는 17,752 및 26,150 성과 제한주식단위(PRSUs)가 무상으로 보통주로 전환/취득된 것, ESPP를 통한 254주 매수, 그리고 보통주 21,801주를 주당 $13.10에 매도한 사실이 기재되어 있습니다. 거래 후 보고된 실질 소유는 참조한 항목에 따라 134,357주에서 160,507주 사이이며, 파생 보유는 1대1 비율로 보통주로 전환되었습니다.
Kristen Cunningham, Chief Sales Officer de LifeVantage Corp (LFVN), a déclaré des changements dans sa détention bénéficiaire via un Formulaire 4 couvrant des opérations datées du 31/08/2025. Le dépôt indique la conversion/acquisition de 17 752 et 26 150 unités d'actions restreintes liées à la performance (PRSUs) en actions ordinaires sans contrepartie financière, un achat ESPP de 254 actions et la vente de 21 801 actions ordinaires au prix de $13,10 par action. Après ces opérations, la détention bénéficiaire déclarée varie entre 134 357 et 160 507 actions selon la ligne consultée; les instruments dérivés ont été convertis en actions ordinaires à raison d'une pour une.
Kristen Cunningham, Chief Sales Officer von LifeVantage Corp (LFVN), meldete Änderungen ihres wirtschaftlichen Eigentums in einem Form 4 für Transaktionen datiert 31.08.2025. Die Einreichung zeigt die Umwandlung/Erwerb von 17.752 und 26.150 performance-restricted Stock Units (PRSUs) in Stammaktien ohne Barzahlung, einen ESPP-Kauf von 254 Aktien sowie den Verkauf von 21.801 Stammaktien zu $13,10 je Aktie. Nach den Transaktionen liegt das gemeldete wirtschaftliche Eigentum je nach gewählter Zeile zwischen 134.357 und 160.507 Aktien; derivative Bestände wurden eins zu eins in Stammaktien umgewandelt.